Enable Accessibility
Enable Accessibility
Better Health,
Brighter Future
Newsroom
Careers
Investors
Patients
HCPs
Worldwide
Who We Are
About Takeda
How can we do more for our patients?
Everything at Takeda starts with this question.
Learn more
Company Information
Company Facts & Japan offices
History
Worldwide Offices
Executive Leadership
Positions
Takeda Global Headquarters
Design Concept
Where we work
Corporate Philosophy
Corporate Governance
Values and Corporate Governance
Board of Directors
Nomination Committee and Compensation Committee
Audit and Supervisory Committee and Internal Audit
Our Management
Charters and Reports, etc.
Risk & Crisis Management
Global Ethics & Compliance / Global Code of Conduct
Transparency Disclosures
EFPIA Disclosure Code Reports
Patient Group Disclosures
Contact Us
Celebrating the grand opening of Takeda Global Headquarters
LEARN MORE
What We Do
Our Business
We will become a global, values-based, R&D-driven, biopharmaceutical leader
Learn more
Research & Development
Ecosystem for Health Innovation
Our Pipeline
Clinical Trials
Center for External Innovation
Investigator Initiated Research
Areas of Focus
Oncology
Rare Diseases
Neuroscience
Gastroenterology
Plasma-Derived Therapies
Vaccines
Alliances & Partnerships
Takeda Digital Ventures
Our Products
Manufacturing
Innovation Story
Access to Medicines
Our Approach and Our Position
Hear from Patients
Driving Impact with Partners
Pre- Approval Access
Suppliers
Sustainable Procurement
Supplier Code of Conduct
Supplier Diversity
Pharmaceutical Supply Chain Initiative
Supplier Qualification & Due Diligence
Shire Supplier Information
Takeda Supplier Solutions Portal
Supplier Registration Process via Ariba Commerce Cloud
T-CiRA
About T-CiRA
Leaders Message
What we do
Portfolios
Projects
Inside T-CiRA
Research Achievements
Future of iPSC
We focus on our core therapeutic areas.
LEARN MORE
Our Stories
Our Stories
Two centuries. Countless innovations. One vision.
Learn more
All Stories
Corporate Responsibility
Takeda's CSR
Takeda is committed to addressing the world’s biggest challenges to sustainable development over the long term.
LEARN MORE
Programs in Action
Takeda Chair in Global Child Health
Takeda Initiative for the Global Fund
Global CSR Program
Apply for Funding
Leaders Driving Change
Purpose led-Sustainability at Takeda
Patient
People
Planet
Governance
Reporting on Sustainability
TAKEDA LIFE THEATER, Embark on a journey of discovery inside the human body!
LEARN MORE
HOME
Newsroom
Shire News Releases
Share:
Newsroom
Global News Releases
Statements
In the News
Featured Topics
Corporate Materials
Social Media
Shire News Releases
Enter
All
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
December 2018
December 18, 2018
12/18/2018
Rule 2.9 announcement
December 17, 2018
12/17/2018
FDA approves Shire’s Motegrity™ (prucalopride), the only serotonin-4 receptor agonist for adults with Chronic Idiopathic Constipation (CIC)
December 14, 2018
12/14/2018
Director/PDMR Shareholding
December 14, 2018
12/14/2018
Rule 2.9 announcement
December 13, 2018
12/13/2018
Rule 2.9 announcement
December 12, 2018
12/12/2018
Rule 2.9 announcement
December 11, 2018
12/11/2018
Rule 2.9 announcement
December 7, 2018
12/7/2018
Rule 2.9 announcement
December 6, 2018
12/6/2018
Rule 2.9 Announcement
2
3
4
5
6
TOP
Close
